Sherbrooke Park Advisers’s Cytek Biosciences CTKB Stock Holding History

Sherbrooke Park Advisers’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,314	Closed	-$89.5K	–	568
2025 Q1	$89.5K	Sell	22,314 -19,460	-47%	-$101K	0.04%	525
2024 Q4	$271K	Sell	41,774 -62,612	-60%	-$373K	0.09%	451
2024 Q3	$578K	Buy	104,386 +74,402	+248%	+$422K	0.13%	250
2024 Q2	$167K	Sell	29,984 -55,850	-65%	-$335K	0.03%	790
2024 Q1	$576K	Buy	+85,834	New	+$679K	0.11%	318
2023 Q4	–	Sell	-15,656	Closed	-$86.4K	–	505
2023 Q3	$86.4K	Buy	+15,656	New	+$126K	0.03%	465

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Sherbrooke Park Advisers's CTKB Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 22,314 shares — an estimated $89.5K sold.

Sherbrooke Park Advisers first reported a position in CTKB in Q3 2023 and held it in 6 quarters. The position peaked at $578K in Q3 2024. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

Sherbrooke Park Advisers reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 22,314 Cytek Biosciences shares in Q2 2025, an estimated $89.5K.
Sherbrooke Park Advisers first reported a position in Cytek Biosciences in Q3 2023 and held it in 6 quarters.
Sherbrooke Park Advisers's Cytek Biosciences position peaked at $578K in Q3 2024.
158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.